Strides Pharma Science（STAR）株式概要
ストライド・ファーマ・サイエンス社は、アフリカ、オーストラリア、北米、ヨーロッパ、アジア、インド、そして国際的に医薬品の開発、製造、販売を行っている。 詳細
STAR Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Strides Pharma Science Limited 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | ₹1,044.60 |
| 52週高値 | ₹1,231.00 |
| 52週安値 | ₹768.65 |
| ベータ | 0.34 |
| 1ヶ月の変化 | -9.71% |
| 3ヶ月変化 | 20.57% |
| 1年変化 | 33.53% |
| 3年間の変化 | 165.30% |
| 5年間の変化 | 26.22% |
| IPOからの変化 | 16.63% |
最新ニュース
ナラティブの更新 • Jun 01
STAR: Upcoming Results, Dividend Proposal And Auditor Change Will Shape Balanced Outlook
Analysts have kept the price target for Strides Pharma Science broadly steady at about ₹1,119, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially change their valuation view. What's in the News A board meeting is scheduled on May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
ナラティブの更新 • May 17
STAR: Upcoming Results And Dividend Decision Will Shape Fairly Valued Outlook
Analysts have raised their price target on Strides Pharma Science from ₹1,078.50 to ₹1,264.00, citing updated assumptions that include higher projected revenue growth, a slightly stronger profit margin profile, a modestly lower discount rate, and a somewhat higher future P/E multiple. What's in the News A board meeting is scheduled on May 18, 2026, to review and approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026 (Key Developments).
ナラティブの更新 • Apr 28
STAR: Higher Revenue And Margin Assumptions Will Support Stronger Returns Ahead
Analysts have maintained their price target for Strides Pharma Science at ₹1,409, citing updated assumptions that reflect slightly higher revenue growth and profit margin expectations, along with a modestly lower future P/E multiple in their models. Valuation Changes Fair Value: Model fair value remains unchanged at ₹1,409.0 per share.ナラティブの更新 • Apr 13
STAR: Upcoming Results Meeting And Revised Assumptions Will Support Bullish Thesis
Analysts have lifted their price target on Strides Pharma Science from ₹1,085 to ₹1,119, pointing to revised assumptions that include slightly higher revenue growth, a modestly lower profit margin and a small uplift in the future P/E multiple. What's in the News A board meeting is scheduled for January 30, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other agenda items (company filing).Recent updates
ナラティブの更新 • Jun 01
STAR: Upcoming Results, Dividend Proposal And Auditor Change Will Shape Balanced Outlook
Analysts have kept the price target for Strides Pharma Science broadly steady at about ₹1,119, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially change their valuation view. What's in the News A board meeting is scheduled on May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.ナラティブの更新 • May 17
STAR: Upcoming Results And Dividend Decision Will Shape Fairly Valued Outlook
Analysts have raised their price target on Strides Pharma Science from ₹1,078.50 to ₹1,264.00, citing updated assumptions that include higher projected revenue growth, a slightly stronger profit margin profile, a modestly lower discount rate, and a somewhat higher future P/E multiple. What's in the News A board meeting is scheduled on May 18, 2026, to review and approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026 (Key Developments).ナラティブの更新 • Apr 28
STAR: Higher Revenue And Margin Assumptions Will Support Stronger Returns Ahead
Analysts have maintained their price target for Strides Pharma Science at ₹1,409, citing updated assumptions that reflect slightly higher revenue growth and profit margin expectations, along with a modestly lower future P/E multiple in their models. Valuation Changes Fair Value: Model fair value remains unchanged at ₹1,409.0 per share.ナラティブの更新 • Apr 13
STAR: Upcoming Results Meeting And Revised Assumptions Will Support Bullish Thesis
Analysts have lifted their price target on Strides Pharma Science from ₹1,085 to ₹1,119, pointing to revised assumptions that include slightly higher revenue growth, a modestly lower profit margin and a small uplift in the future P/E multiple. What's in the News A board meeting is scheduled for January 30, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other agenda items (company filing).ナラティブの更新 • Mar 30
STAR: Higher Revenue Assumptions Will Support Stronger Profit Margins Ahead
Analysts have raised their price target on Strides Pharma Science from ₹1,220 to ₹1,409, citing updated assumptions for revenue growth, profit margins and future P/E that collectively support a higher fair value estimate under a slightly lower discount rate. What's in the News A board meeting is scheduled for January 30, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).ナラティブの更新 • Mar 16
STAR: Future Earnings Meeting And Margin Outlook Will Support Bullish Thesis
Analysts have lifted their price target on Strides Pharma Science from ₹937 to ₹1,085, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, as well as a slightly lower discount rate. What's in the News The board has scheduled a meeting on January 30, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).ナラティブの更新 • Sep 05
Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach
With both Net Profit Margin and Revenue Growth forecasts remaining stable, analysts made no substantive changes to their outlook, resulting in the consensus price target for Strides Pharma Science holding steady at ₹1078. What's in the News Board meeting scheduled to consider and approve Q1 FY26 unaudited financial results, share allotment, and amendments to the company's fair disclosure policy.
新しいナラティブ • Feb 10
US Product Launches And ESG Leadership Will Strengthen Future Market Position
Streamlined focus on high-margin operations and U.S. market expansion indicate a strong growth trajectory and improved future earnings.分析記事 • Nov 01
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Even though Strides Pharma Science Limited's ( NSE:STAR ) recent earnings release was robust, the market didn't seem to...分析記事 • Oct 21
Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...分析記事 • Aug 14
After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...分析記事 • Apr 04
Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
With a median price-to-sales (or "P/S") ratio of close to 2.4x in the Pharmaceuticals industry in India, you could be...分析記事 • Feb 29
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Dec 23
Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Strides Pharma Science Limited ( NSE:STAR ) shareholders have had their patience rewarded with a 31% share price jump...分析記事 • Sep 26
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jun 08
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Aug 02
Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Last week saw the newest quarterly earnings release from Strides Pharma Science Limited ( NSE:STAR ), an important...分析記事 • Jun 25
Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...株主還元
| STAR | IN Pharmaceuticals | IN 市場 | |
|---|---|---|---|
| 7D | -6.0% | -0.06% | -0.8% |
| 1Y | 33.5% | 7.4% | -2.9% |
業界別リターン: STAR過去 1 年間で7.4 % の収益を上げたIndian Pharmaceuticals業界を上回りました。
リターン対市場: STAR過去 1 年間で-2.9 % の収益を上げたIndian市場を上回りました。
価格変動
| STAR volatility | |
|---|---|
| STAR Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.8% |
安定した株価: STAR 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: STARの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1990 | 3,301 | Badree Komandur | www.strides.com |
ストライド・ファーマ・サイエンス社は、アフリカ、オーストラリア、北米、ヨーロッパ、アジア、インド、および国際的に医薬品の開発、製造、販売を行っている。医薬品とバイオ医薬品の2つのセグメントで事業を展開している。同社は、錠剤、ハード・ソフトゼラチンカプセル、分包、液剤、点鼻薬、ゲル剤、粉末剤、固形剤、軟膏剤、クリーム剤など様々な形態のジェネリック医薬品を提供している。また、レネルブ、ユニブロール、コンビアート、デュオタブ、ビタファーの各ブランドで、女性の健康、中枢神経系、循環器、糖尿病、皮膚科、プロバイオティクスなどの慢性治療用のブランドジェネリック医薬品、および機関投資家向けの抗レトロウイルス薬、抗マラリア薬、抗結核薬、肝炎薬、その他の感染症治療薬の開発も行っている。同社は以前はStrides Shasun Limitedとして知られていたが、2018年7月にStrides Pharma Science Limitedに社名を変更した。Strides Pharma Science Limitedは1990年に設立され、インドのベンガルールに本社を置いている。
Strides Pharma Science Limited 基礎のまとめ
| STAR 基礎統計学 | |
|---|---|
| 時価総額 | ₹96.28b |
| 収益（TTM） | ₹5.56b |
| 売上高(TTM) | ₹48.59b |
17.3x
PER（株価収益率2.0x
P/SレシオSTAR は割高か？
公正価値と評価分析を参照収益と収入
| STAR 損益計算書（TTM） | |
|---|---|
| 収益 | ₹48.59b |
| 売上原価 | ₹19.59b |
| 売上総利益 | ₹29.00b |
| その他の費用 | ₹23.44b |
| 収益 | ₹5.56b |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 60.34 |
| グロス・マージン | 59.69% |
| 純利益率 | 11.45% |
| 有利子負債／自己資本比率 | 53.0% |
STAR の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
0.5%
現在の配当利回り8%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/07 23:37 |
| 終値 | 2026/06/05 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Strides Pharma Science Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14
| アナリスト | 機関 |
|---|---|
| Aditya Khemka | Ambit Capital |
| Harith Ahamed | Avendus Spark |
| Prakash Agarwal | Axis Capital Limited |